American Society of Clinical Oncology (ASCO)
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
* ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins * WU-KONG28 is the first global randomized phase 3 study with positive results for an oral, chemo-free, targeted monotherapy regimen...
The 3rd TÜV Rheinland Quality Fest Officially Kicks Off
Marking the 40th Anniversary in Greater China and Co-Creating a New Chapter of Quality HONG KONG, May 29, 2026 /PRNewswire/ -- Ahead of the upcoming 19th "World Accreditation Day" on June 9, the 3rd TÜV Rheinland Quality Fest has officially commenced. Building on the strong momentum and industry...
Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
* Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented. * The efficacy data highlight how the combination of elacestrant and capivasertib has the potential to address key resistance mechanisms for pa...
Fox ESS Announces Its Rebrand Ahead of SNEC Exhibition, Unveiling A New Brand Journey
WENZHOU, China, May 28, 2026 /PRNewswire/ -- Fox ESS, a global leader in renewable energy solutions, today announced its rebrand, an important step in the brand's ongoing journey of innovation, trust, and long-term commitment to a more resilient future. After seven years of growth and continued r...
Axi Brings Award-Winning Funded Trading Program and Manchester City Partnership to FMAS:26 in Cape Town
SYDNEY, May 28, 2026 /PRNewswire/ -- Axi, the global FX and CFD broker serving traders across more than 100 countries, attended the Finance Magnates Africa Summit (FMAS:26) on 26 and 27 May 2026 at the Cape Town International Convention Centre in Cape Town, South Africa. Africa is one of the fas...
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test
SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions
Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) h...
Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
HONG KONG, May 27, 2026 /PRNewswire/ -- On 27 May 2026, Fortune China magazine released its 2026 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highlights...
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued
Encouraging Safety and Tolerability Data
SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2 in Chicago, Illin...
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
* Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. * Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential i...
Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
SHANGHAI, May 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) at the 2026 American S...
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
* Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506) * Efficacy and safety of lunbotinib fumarate (A...
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
TAIPEI, May 21, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy ofTSY-310, a novel bispecific antibody-drug conjugate (ADC), has been selected for presentation at the American Society of Clinic...
Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
At ASCO 2026, Lunit will present precision patient stratification and biomarker-driven oncology research through AI-powered HER2/IHC biomarker quantification and spatial tumor microenvironment analysis. SEOUL, South Korea, May 21, 2026 /PRNewswire/ -- Lunit, a leading provider of AI for cancer d...
Fox ESS Celebrates Strong Momentum with Integrated Solar Storage & Charging Solutions at Smart Energy 2026
SYDNEY, May 9, 2026 /PRNewswire/ -- Fox ESS, a global leader in renewable energy solutions, attended Smart Energy 2026 during 6-7 May as a platinum sponsor. At the event, Fox ESS showcased its next-generation approach to solar storage and EV charging solution, delivering a seamless, future-ready ...
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review ...
Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a ...
139th Canton Fair: Creativity and Innovation Sparks New Possibilities in Gifts & Decorations Category
GUANGZHOU, China, April 25, 2026 /PRNewswire/ -- Phase 2 of the 139th Canton Fair is spotlighting a new generation of creativity in the Gifts & Decorations category, where exhibitors are blending craftsmanship, technology, sustainability, and cultural storytelling to redefine modern gifting and h...
2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 317 media titles]
2026-06-08 10:16
Visa Partners with OpenAI to Power the Next Generation of AI Commerce
[Picked up by 304 media titles]
2026-06-11 09:30Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 297 media titles]
2026-06-05 19:08
QuettaFlow Technologies Strengthens Global Strategic Alliance with Lead Wealth and Showcases VasEdge at COMPUTEX Taipei 2026
[Picked up by 294 media titles]
2026-06-11 10:00
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
Tuniu Announces Unaudited First Quarter 2026 Financial Results
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
